Three Out of Four Doctors Believe We Have a Long Way to Go to Achieve COVID-19 Community Immunity
Study 15 in Sermo’s COVID-19 Real Time Barometer of nearly 4,000 global doctors revealed that 74 percent of physicians believe it will take at least 7
Related Articles
Q Bio Unveils New MRI Technology – Tensor Field Mapping – Advancing Measurement in Medical Imaging
Q Bio Inc., an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM), a new technology for Magnetic Resona
Plastic Degradation Company, Breaking, Emerges from Stealth with Naturally-Derived Solution to Degrade Multiple Plastics with $10.5M in Seed Funding
Breaking, a plastic degradation and synthetic biology company, gestated at Colossal Biosciences based on a core discovery out of the Wyss Institute fo
TELUS International and Appian Expand Strategic Partnership to Help Companies Simplify Complex Business Processes Through an Innovative, Low-Code Automation Platform
TELUS International (NYSE and TSX: TIXT), a leading digital customer experience (CX) innovator that designs, builds, and delivers next-generation solu
Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax
Following to the previous information on March 11th, 2024, we are excited to share our latest development status. We are pleased to announce the proto
Kazakhstan Startup CerebraAI Relocates Headquarters to Silicon Valley to Address Severe Emergency Care Diagnostics Gap through Novel Generative AI Medical Imaging Approach
CerebraAI is developing its GenAI algorithm to predict personalized “norms” in brain imaging based on NCCT scans for acute ischemic stroke detection.
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD